Therapix Biosciences Ltd. (TRPX): Price and Financial Metrics
TRPX Price/Volume Stats
|Current price||$0.32||52-week high||$4.69|
|Prev. close||$0.62||52-week low||$0.25|
|Day high||$0.40||Avg. volume||1,587,268|
|50-day MA||$0.53||Dividend yield||N/A|
|200-day MA||$1.06||Market Cap||1.12M|
TRPX Stock Price Chart Interactive Chart >
Therapix Biosciences Ltd. (TRPX) Company Bio
Therapix Biosciences Ltd., a specialty pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01 targeted to the ultra-low dose formulation of dronabinol, combined with sublingual and nasal delivery methods, to provide treatment for Mild Cognitive Impairment (MCI). The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is based in Tel Aviv, Israel.
TRPX Latest News Stream
|Loading, please wait...|
TRPX Latest Social Stream
View Full TRPX Social Stream
Latest TRPX News From Around the Web
Below are the latest news stories about Therapix Biosciences Ltd that investors may wish to consider to help them evaluate TRPX as an investment opportunity.
Nasdaq has informed Therapix Biosciences (TRPX) that it will delist its American Depositary Shares (ADSs) effective tomorrow, July 2, at the open.Yesterday, an Israeli court granted a temporary injunction against the company barring it from making any changes to its share capital or adopting any resolution outside of the normal...
Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court.
Therapix Biosciences (TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and warrants to purchase up to 2.6M ADSs in a private placement.The private placement is expected to result in gross proceeds to Therapix of $2.6M.Net proceeds will be used...
Therapix Biosciences (NASDAQ:TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and w
TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive…
TRPX Price Returns